TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change of Acellular growth retardation ability (AGRA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: repigmentation in the previously depigmented patch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants With a 6-month Sustained Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time From First Dose to Urinary Continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in dosage of opioid and co-analgesic treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local control at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of AMG 510
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: multi-omic biomarker predictors of ASD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluorescence intensity in breast cancer tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Distance from needle tip to center of IJV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxidative protection index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative Endoscopic Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of self taken swabs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in nocturnal enuresis frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial integrity of the radial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of tumor response (CR + CRU + PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC0-t) of Glycopyrronium Bromide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of radiographic FAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genomic alterations in tumoral tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Analysis of cell-free DNA (cfDNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Analysis of circulating tumor cells (CTC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Nasal Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: World Health Organisation Five Well-being Index (WHO-5)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in wound healing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Altered pain experience associated with chronic wounds
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of proven suicide attempts
Endpoint domain: Mortality/survival
Primary endpoint: Percent reduction of longest diameter of tumor in millimeters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective Tumor Response Rate (by RECIST criteria)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Effect on tumor morphometry, as measured by RENAL score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recruitment and retention of subjects
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline in Averaged Postprandial Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: New or Recurrent HIV Disease Progression Event Including Death
Endpoint domain: Mortality/survival
Primary endpoint: CPET performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of eligible patients receiving the decision aid
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Resternotomy
Endpoint domain: Adverse events/effects
Primary endpoint: area under the concentration-time curve (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the concentration time curve (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self Reported Nausea and Vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: change in probability of complete remission (proteinuria < 0.3 g/day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Correlation between serum biomarkers and HVPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of EF5 binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Child Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Child Fear
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of inquiries to the German self-help group
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from baseline of Apnea-Hypopnea Index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rabies neutralizing antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cobb angle of the injured vertebral body
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean change in PANSS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Knee Disability Committee (IKDC) Survey
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Anterior Cruciate Ligament-Return to Sport after Injury (ACL-RSI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fasting and postprandial plasma triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Need to visit the emergency department or acute evaluation outpatient clinic
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Complete blood count ordered in the index evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of HTL0018318
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) of HTL0018318
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average time to glycemic target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ESS (Epworth Sleepiness Scale) change from baseline
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percentage of Participants With Worsening Heart Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: All Cause of Deaths
Endpoint domain: Mortality/survival
Primary endpoint: Virological cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inherited differences in plaque distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Severity of gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proximal arm tenderness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of Mitoxantrone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of Sorafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Minimal Residual Disease Negative (MRDneg) Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of anterior chamber inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Change in average FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Intraoperative Ocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of adherence to HAART
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in intellectual functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Difference in quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical assessment scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mycological status of fungi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: worsening of WHO functional class
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in PASAT Cognitive Fatigue scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Time required to remove the needle from syringe
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder rate for marionette lines after treatment with Etermis 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder rate for lips after treatment with Etermis 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder rate for NLFs after treatment with Etermis 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder rate for marionette lines after treatment with Etermis 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder rate for lips after treatment with Etermis 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Achieved Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of vascular death
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of non-fatal stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of Participants With Controlled Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urinary symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Post-Treatment change in hearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity of the vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Recruited Per Month
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement of treatment satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of events of stroke
Endpoint domain: Mortality/survival
Primary endpoint: change in crying
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of population reporting with Major Adverse Cardiac Event
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of population reporting with Ischemia Driven Major Adverse Cardiac Event (ID MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Overall failure rate of the para-vertebral block
Endpoint domain: Adverse events/effects
Primary endpoint: Change in mean sitting systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intraprostatic hormone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: SD-OCT macular subfield thicknesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Required number of anti-VEGF injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Subjects Reporting Adequate Relief From IBS Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Relapse Free at 24 Months
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of HRD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Chemistry and Hematology Laboratory Measures - Creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With Complete Eschar Removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EQ-Visual Analogue Scale result
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Day 3 high quality embryo proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence rate at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: End-of-cycle DLT rate
Endpoint domain: Adverse events/effects
Primary endpoint: Isotretinoin toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: number of pathological deliveries
Endpoint domain: Mortality/survival
Primary endpoint: maternal satisfaction with delivery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cost-effectiveness of therapeutic strategies
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prognosis in patients with bacteremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiological response in patients with bacteremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical prognosis related to piperacillin/tazobactam serum concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface Electromyography of shoulder muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in High Density Lipoprotein Cholesterol (HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gene expression in airway epithelia and inflammatory cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of epileptic seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Actual Peri-operative Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Contents of total and individual carotenoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vitamin D content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tenacity and frequency of soft tissue adhesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Gene Expression Profile of Peripheral Blood Mononuclear Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of children being transfused intraoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Documented transfusion indication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Best objective response of target liver lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: MMSE changes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: HbA1c Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in frequency of spontaneous bowel movement (SBM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of subjects reporting treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: SBT (% dose recovered at 90 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SBT (time to 50% recovery)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced the Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of common mental disorders
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent of time in normoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Adult Attention Deficit Hyperactivity Disorder (ADHD) Self-Report Scale (ASRS) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Adult ADHD Quality of Life (AAQoL) Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: State anxiety level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of acute compartment syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of rhinitis symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence rate of chronic kidney disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: awareness rate of chronic kidney disease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: treatment rate of chronic kidney disease
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: degree of decreased glomerular filtration rate in chronic kidney patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time from randomization to fulfillment of extubation criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ARNm expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EuroQoL (EQ-5D)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants with Decrease in Nasal Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trophoblastic invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to persistent decrease in Creatinine clearance (CrCL) of 40% or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to persistent increase in Serum Creatinine (SCr) of 80% or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to progression to end-stage renal disease (ESRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in cardiac sympathetic nerve activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in renal sympathetic nerve activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in muscle sympathetic nerve activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of HM61713 and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve from zero to infinity (AUC) of HM61713 and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal half life (t1/2) of HM61713 and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relief of pain, stiffness, and discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance to Raw Egg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recourse to prostatic surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Knee Osteoarthritis Outcome Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Isometric strength tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of device or procedure related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of device or procedure related clinically significant tamponade/perforation
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of symptomatic pulmonary vein stenosis and atrioesophageal fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of documented symptomatic atrial fibrillation, atrial flutter and atrial tachycardia episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Differences in dermal and serum opiate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Differences in neuropeptides involved in atopic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Occurrence of a cardiovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Completely healing time of the target ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes